Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Desert Gold Report Results from 3,900 Meter Phase 2 Exploration Drill Program (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Pfizer Inc PFE

Alternate Symbol(s):  N.PFE

Healthcare
Pfizer Inc. is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment is engaged in the science-based biopharmaceutical business. Its Biopharma segment includes the Pfizer Oncology Division, the Pfizer U.S. Commercial Division, and the... see more

Recent & Breaking News (NYSE:PFE)

CHMP Confirms Prior Opinion Regarding Marketing Authorization in Europe for Pfizer's XELJANZ® (tofacitinib citrate)

Business Wire July 25, 2013

The Reason It Trades, What's Moving PFE, C, IBM and CMG

Marketwired July 25, 2013

The Real Story Behind BIDU, PFE and JCI

Marketwired July 25, 2013

Pfizer Provides Historical Consolidated Statements of Income with the Animal Health Business (Zoetis) Reported as a Discontinued Operation

Business Wire July 23, 2013

Luck of the Irish: Pharma Returns a Bit of the Gold to Ireland as Capital Investment Rises, an Industrial Info News Alert

Marketwired July 18, 2013

Pfizer Provides Update on Global Regulatory Approvals and Launches of XELJANZ® (tofacitinib citrate) for the Treatment of Rheumatoid Arthritis

Business Wire July 15, 2013

Is San Diego Ready for an Aging Population? New Local Survey Reveals San Diego-Area Residents Concerned about Their City and Themselves as They Get Old; New Website, "By the Decades" Healthy Aging Checklist and Aging Communities Toolkit Offers Help

Business Wire July 11, 2013

Is Boston Ready for an Aging Population? New Local Survey Reveals Bostonians' Concerned about Their City and Themselves as They Get Old; New Website, Healthy Aging "By the Decades" Checklist and Aging Communities Toolkit Offers Help

Business Wire July 11, 2013

Is Atlanta Ready for an Aging Population? New Local Survey Reveals Atlanta-Area Residents Concerned about Their City and Themselves as They Get Old; New Website, Healthy Aging "By the Decades" Checklist and Aging Communities Toolkit Offer Help

Business Wire July 11, 2013

Is Kansas City Ready for an Aging Population? New Local Survey Reveals Kansas City-Area Residents Concerned about Their City and Themselves as They Get Old; New Website, "By the Decades" Healthy Aging Checklist and Aging Communities Toolkit Offers Help

Business Wire July 11, 2013

FDA Accepts Eliquis® (apixaban) Supplemental New Drug Application for Review for Prophylaxis of Deep Vein Thrombosis Following Hip Or Knee Replacement Surgery

Business Wire July 11, 2013

New survey on Atlanta Attitudes Toward Aging To Be Released Thursday, July 11

Business Wire July 10, 2013

Pfizer Receives European Approval To Expand Use Of Prevenar 13* To Adults Aged 18 To 49 Years For The Prevention Of Invasive Pneumococcal Disease

Business Wire July 10, 2013

Trial Results, New Facilities, Approved Labels, Spinoffs, and M&As Support Long-Term Growth Strategies - Research Report on Pfizer, Johnson & Johnson, Merck, Zoetis, and AstraZeneca

PR Newswire July 4, 2013

Lpath to Present at the 2013 JMP Healthcare Conference on July 9

Marketwired July 3, 2013

Acura Pharmaceuticals Provides Update on Partnership With Pfizer

Marketwired July 1, 2013

Eliquis® (apixaban) Demonstrated Comparable Efficacy and Significantly Lower Rates of Major Bleeding in Patients Compared to Current Standard of Care for the Treatment of Acute Venous Thromboembolism

Business Wire June 30, 2013

Pfizer Declares 24-Cent Third-Quarter 2013 Dividend

Business Wire June 27, 2013

Pfizer Announces Final Results of Zoetis Exchange Offer

Business Wire June 27, 2013

Advil® Is the Official Pain Reliever of Tough Mudder® Bringing #ReliefinAction to "Probably the Toughest Event on the Planet"

Business Wire June 26, 2013